Peter Loftus

More employers are requiring weigh-ins, app tracking and health coaching before approving GLP-1s for losing weight—or dropping coverage altogether.

After shedding its oncology business just over a decade ago, GSK is building it back with a $10.6 billion deal.

Moderna shares rose 3.5% Thursday after an advisory committee voted to recommend the U.S. Food and Drug Administration approve the biotech’s proposed new flu shot for people 50 and older. The FDA had initially [declined to conside](https://www.wsj/health/pharma/fda-refuses-to-consider-approving

The proposed acquisition will be the company’s biggest deal in more than a decade and represents an early move by new CEO Kai Beckmann to bolster the business.

Moderna shares were up more than 10% Friday after the biotech company revealed a new effort to make a treatment for autoimmune disorders and outlined several experimental drug projects that could help it diversify beyond Covid-19 vaccines in coming years. The company that gained fame for its messen

Millions of older Americans are on the cusp of more affordable access to popular weight-loss drugs when a major Medicare coverage expansion kicks in July 1.

The market leader in obesity shots, Lilly hasn’t made a major dent in the pill market yet.

The market leader in obesity shots, Lilly hasn't made a major dent in the pill market yet.

Lipfendra, to be taken once a day, is designed to help lower cholesterol levels beyond what statins alone can achieve.

Peter Loftus U.S. regulators approved a first-of-its kind pill from Merck that is designed to help lower cholesterol levels beyond what statins alone can achieve.